Rule 3.19A.2

Appendix 3Y

Change of Director's Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX's property and may be made public.

Introduced 30/9/2001. Amended 01/01/11

Name of Entity:	Chimeric Therapeutics Limited (ASX: CHM)	
ABN:	68 638 835 828	

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director:	Paul Hopper
Date of Last Notice:	28 August 2023

Part 1 - Change of director's relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of "notifiable interest of a director" should be disclosed in this part.

Direct or Indirect Interest	Indirect		
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Director related entities		
Date of change	31 March 2024		
No. of securities held prior to change			
The second second process of termings		Shares	Options
	Direct	1,232,142	-
	Indirect	93,762,432	2,941,176
	Total	94,994,574	2,941,176
Class	СНМО Ор	otions	
Number acquired			
		Shares	Options
	Direct	-	-
	Indirect	Ī	-
	Total	-	-
Number disposed			
		Shares	Options
	Direct	Shares	Options -
	Direct Indirect	Shares -	Options - 2,941,176 2,941,176

⁺ See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y **Change of Director's Interest Notice**

Value/Consideration	n/a		
Note: If consideration is non-cash, provide details and estimated			
valuation			
No. of securities held after change			
		Shares	Options
	Direct	1,232,142	-
	Indirect	93,762,432	-
	Total	94,994,574	-
	'		
Nature of change	CHMO options expired 31 Mar 2024		
Example:			
on-market trade, off-market trade, exercise of options, issue			
of securities under dividend reinvestment plan, participation			
in buy-back			

Part 2 – Change of director's interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of "notifiable interest of a director" should be disclosed in this part.

Detail of contract	N/A
Nature of interest	N/A
Name of registered holder (if issued securities)	N/A
Date of change	N/A
No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed	N/A
Interest acquired	N/A
Interest disposed	N/A
Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation	N/A
Interest after change	N/A

Appendix 3Y Page 2 01/01/2011

⁺ See chapter 19 for defined terms.

Part 3 – Closed period

Were the interests in the securities or contracts detailed above traded during a +closed period where prior written clearance was required?	I .
If so, was prior written clearance provided to allow the trade to proceed during this period?	N/A
If prior written clearance was provided, on what date was this provided?	N/A

01/01/2011 Appendix 3Y Page 3

⁺ See chapter 19 for defined terms.